Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Share-based Compensation (2021 - 2025)

Verrica Pharmaceuticals has reported Share-based Compensation over the past 5 years, most recently at $686000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $686000.0 for Q4 2025, down 9.26% from a year ago — trailing twelve months through Dec 2025 was $3.3 million (down 53.69% YoY), and the annual figure for FY2025 was $3.3 million, down 53.69%.
  • Share-based Compensation for Q4 2025 was $686000.0 at Verrica Pharmaceuticals, down from $718000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for VRCA hit a ceiling of $9.7 million in Q3 2023 and a floor of $686000.0 in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $1.4 million (2021), compared with a mean of $1.8 million.
  • Biggest five-year swings in Share-based Compensation: soared 583.86% in 2023 and later tumbled 78.18% in 2024.
  • Verrica Pharmaceuticals' Share-based Compensation stood at $1.3 million in 2021, then dropped by 11.36% to $1.2 million in 2022, then skyrocketed by 77.2% to $2.1 million in 2023, then crashed by 63.57% to $756000.0 in 2024, then decreased by 9.26% to $686000.0 in 2025.
  • The last three reported values for Share-based Compensation were $686000.0 (Q4 2025), $718000.0 (Q3 2025), and $888000.0 (Q2 2025) per Business Quant data.